Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 2:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 346 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Malignant Neoplasm of Prostate Clear all
Terminated Phase 1 Interventional

Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

NCT04541225
View directory record Official record
Conditions
Glioma, Glioma, Malignant, Glioma, Mixed, Glial Cell Tumors, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor, Malignant Tumor of Breast, Advanced Breast Cancer, Advanced Breast Carcinoma, Metastatic Breast Cancer, Metastatic Breast Carcinoma, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration-resistant Prostate Cancer, Castration Resistant Prostatic Neoplasms, Glioblastoma, Recurrent Glioblastoma
Interventions
NUV-422
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Tucson, Arizona • Miami, Florida • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 4, 2026, 2:41 AM EDT
Recruiting Phase 1 Interventional

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

NCT06130995
View directory record Official record
Conditions
Androgen Deprivation Therapy, Locally Advanced Prostate Cancer
Interventions
Relugolix and Enzalutamide
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 4, 2026, 2:41 AM EDT
Active, not recruiting No phase listed Observational

Impact of COVID-19 on GU Disease

NCT04761107
View directory record Official record
Conditions
COVID-19 Infection, Genitourinary Cancer, Benign Urologic Conditions
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
40 Years and older
Enrollment
15,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 4, 2026, 2:41 AM EDT
Recruiting Phase 1 Interventional

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

NCT04729114
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
Interventions
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
24
States / cities
Tucson, Arizona • Anaheim, California • Santa Rosa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 4, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer

NCT01431391
View directory record Official record
Conditions
Prostatic Neoplasm, Prostate Cancer, Prostatic Adenocarcinoma
Interventions
sipuleucel-T, leuprolide acetate
Biological · Drug
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
14
States / cities
Homewood, Alabama • La Jolla, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 4, 2026, 2:41 AM EDT
Recruiting No phase listed Observational

Upright MRI for Prostate Cancer Screening

NCT03474913
View directory record Official record
Conditions
Prostate Cancer, Elevated PSA, Elevated Prostate Specific Antigen
Interventions
Upright MRI, Standard MRI
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 4, 2026, 2:41 AM EDT
Withdrawn No phase listed Observational

Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer

NCT03563352
View directory record Official record
Conditions
Breast Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma, Gastric Carcinoma, Malignant Digestive System Neoplasm, Pancreatic Carcinoma, Prostate Carcinoma
Interventions
Interview, Survey Administration
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 4, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer

NCT01823978
View directory record Official record
Conditions
Castrate Resistent Prostate Cancer
Interventions
BPX-201 vaccine plus AP1903
Biological
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Birmingham, Alabama • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 4, 2026, 2:41 AM EDT
Completed Phase 1 Interventional Results available

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

NCT03218826
View directory record Official record
Conditions
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Prostate Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Solid Neoplasm
Interventions
Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study, PI3Kbeta Inhibitor AZD8186
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
8
States / cities
Aurora, Colorado • Baltimore, Maryland • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 4, 2026, 2:41 AM EDT
Not listed Not applicable Interventional Results available

Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites

NCT04267575
View directory record Official record
Conditions
Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer, Stage IV Prostate Cancer, Stage IV Pancreatic Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Cancer, Stage IV Fallopian Tube Cancer, Stage IV Colon Cancer, Stage IV Colorectal Cancer, Stage IV Liver Cancer, Stage IV Renal Cell Cancer, Stage IV Rectal Cancer, Stage IV Lung Cancer, Stage IV Small Intestinal Cancer, Stage IV Gastric Cancer, Stage IV Bladder Cancer
Interventions
Canady Helios Cold Plasma Scalpel
Device
Lead sponsor
Jerome Canady, M.D.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 4, 2026, 2:41 AM EDT
Completed Phase 2 Interventional

EPO906 Therapy in Patients With Prostate Cancer

NCT00035113
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
epothilone b
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
5
States / cities
Long Beach, California • San Francisco, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 4, 2026, 2:41 AM EDT
Not yet recruiting Early Phase 1 Interventional

Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery

NCT07674771
View directory record Official record
Conditions
Prostate Cancer, Castration Sensitive Prostate Cancer, Metastatic Prostate Cancer, Adaptive Radiotherapy
Interventions
Drug: 68-Ga PSMA11, Adaptive stereotactic ablative radiotherapy (SABR), 68Ga-PSMA-11, Adaptive stereotactive ablative radiotherapy (SABR)
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 4, 2026, 2:41 AM EDT
Completed No phase listed Observational

Biobank for African American Prostate Cancer Research in Florida

NCT03232411
View directory record Official record
Conditions
Prostate Cancer
Interventions
Questionnaires, Saliva Samples, Tumor Tissue
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
20 Years and older · Male only
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 4, 2026, 2:41 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY3022855 In Participants With Breast or Prostate Cancer

NCT02265536
View directory record Official record
Conditions
Neoplasms, Neoplasm Metastasis
Interventions
LY3022855
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 4, 2026, 2:41 AM EDT
Terminated Phase 1Phase 2 Interventional

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT05553639
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
HB-302/HB-301 Alternating 2-Vector Therapy
Biological
Lead sponsor
Hookipa Biotech GmbH
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
Duarte, California • San Marcos, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 4, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer

NCT00667862
View directory record Official record
Conditions
Prostate Cancer
Interventions
Panobinostat
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 4, 2026, 2:41 AM EDT
Active, not recruiting Early Phase 1 Interventional

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

NCT04147494
View directory record Official record
Conditions
Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Head and Neck Carcinoma, Kidney Carcinoma, Lung Carcinoma, Ovarian Carcinoma, Pancreatic Carcinoma, Solid Neoplasm, Uterine Corpus Cancer
Interventions
Computed Tomography, Gallium Ga 68 FAPi-46, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography, 18F-FDG
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 4, 2026, 2:41 AM EDT
Not listed Phase 1 Interventional

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

NCT03129139
View directory record Official record
Conditions
Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach
Interventions
Minnelide™Capsules
Drug
Lead sponsor
Minneamrita Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 4, 2026, 2:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers

NCT01287845
View directory record Official record
Conditions
Diagnostic Imaging
Interventions
BAY1075553
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 21, 2013 · Synced Oct 4, 2026, 2:41 AM EDT
Completed No phase listed Observational

Analyses of Human Samples Collected in Clinical Trials

NCT00339664
View directory record Official record
Conditions
Leukemia, Myeloid, Neoplasm Metastasis, Leukemia, Lymphoid, Prostate Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 100 Years
Enrollment
2,579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2020
U.S. locations
15
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 4, 2026, 2:41 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

NCT06238479
View directory record Official record
Conditions
Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Interventions
LY4101174
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Orlando, Florida • Atlanta, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 4, 2026, 2:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04585750
View directory record Official record
Conditions
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Interventions
rezatapopt, pembrolizumab
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 4, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 4, 2026, 2:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Michigan Genetic Hereditary Testing (MiGHT)

NCT05162846
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Endometrial Cancer, History of Cancer
Interventions
Publicly available genetic testing resources, Virtual genetics navigator, Motivational interviewing (MI)
Other · Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 4, 2026, 2:41 AM EDT